DeutschNewstral
Article
Bbarrons.com on 2019-12-24 15:16
What to Expect from Amgen and Regeneron Stock in 2020, According to an Analyst
Related news
- BAmgen Stock Is Poised to Gain in 2020, Analyst Saysbarrons.com
- BBuy Regeneron Stock, but Not Because of Its Covid-19 Antibody Cocktail, Analyst Saysbarrons.com
- BRegeneron Stock Jumps After Analyst Says Now Could Be a Good Time to Buybarrons.com
- BRegeneron Stock Is Downgraded. Analyst Cites Tough Competition From a Novartis Drug.barrons.com
- TWomen expect competitive Amgen raceThe Folsom Telegraph
- BRegeneron Pharmaceuticals Reports Earnings Tomorrow. Here’s What to Expect.barrons.com
- BAmgen Reports Earnings Tomorrow. Here’s What to Expect.barrons.com
- BRegeneron Stock Climbs as Earnings Come in Strongbarrons.com
- BA Case to Buy Regeneron Stock After Its Recent Tumblebarrons.com
- BAmgen Acquires a Cancer Drug. Expect More Deals.barrons.com
- BA Promising Ebola Drug Isn’t Helping Regeneron Stock. Here’s Why.barrons.com
- PAmgen earnings beat analyst estimatespacbiztimes.com
- BBuy Amgen, UnitedHealth, and Dentsply Sirona Stock, Goldman Sachs Saysbarrons.com
- BAmgen Stock Jumps on Earnings, Covid-19 Trial Announcementbarrons.com
- PAmgen wins lawsuit against Regeneron, Sanofi for violating patentspacbiztimes.com
Regeneron boss backs attempt to block $28bn Amgen acquisitionFinancial Times
Amgen, Regeneron Stocks Go Up as Drugs Bring Cholesterol DownForbes- BIt’s Time to Buy Bristol-Myers Stock, According to 1 Analyst.barrons.com
- BRegeneron Earnings Lift Stock. Here's Why.barrons.com
- BRegeneron Faces More Uncertainty as Rivals Gear Up, Analyst Saysbarrons.com